HER2-positive breast cancer: a new piece of the puzzle

Mené sur 602 patientes atteintes d'un cancer du sein HER2+ de stade avancé ayant progressé après au moins deux thérapies ciblées anti HER2 , cet essai international de phase III évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité du trastuzumab emtansine

Résumé en anglais

In 1987, overexpression of the growth-factor receptor HER2 was identified as a negative predictor of outcome in breast cancer patients. The protein turned out to be a druggable target, and the creation of trastuzumab—a humanised monoclonal antibody targeting the extracellular domain of HER2—not only revolutionised the treatment in this disease subset, but also marked the advent of targeted therapy in breast oncology...